Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Finished Goods (2016 - 2018)

Anika Therapeutics (ANIK) has disclosed Finished Goods for 8 consecutive years, with $4.6 million as the latest value for Q3 2018.

  • On a quarterly basis, Finished Goods fell 20.31% to $4.6 million in Q3 2018 year-over-year; TTM through Sep 2018 was $4.6 million, a 20.31% decrease, with the full-year FY2017 number at $4.7 million, up 3.02% from a year prior.
  • Finished Goods was $4.6 million for Q3 2018 at Anika Therapeutics, down from $5.2 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $6.8 million in Q1 2018 to a low of $3.1 million in Q1 2015.
  • A 5-year average of $4.6 million and a median of $4.6 million in 2018 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: skyrocketed 147.88% in 2014, then tumbled 41.93% in 2015.
  • Anika Therapeutics' Finished Goods stood at $3.2 million in 2014, then increased by 9.3% to $3.5 million in 2015, then rose by 29.64% to $4.5 million in 2016, then increased by 3.02% to $4.7 million in 2017, then dropped by 0.81% to $4.6 million in 2018.
  • Per Business Quant, the three most recent readings for ANIK's Finished Goods are $4.6 million (Q3 2018), $5.2 million (Q2 2018), and $6.8 million (Q1 2018).